Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes
- 5 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 63 (8), 1576-1587
- https://doi.org/10.1007/s00125-020-05179-4
Abstract
Aims/hypothesis Self-antigen-specific T cell responses drive type 1 diabetes pathogenesis, but alterations in innate immune responses are also critical and not as well understood. Innate immunity in human type 1 diabetes has primarily been assessed via gene-expression analysis of unstimulated peripheral blood mononuclear cells, without the immune activation that could amplify disease-associated signals. Increased responsiveness in each of the two main innate immune pathways, driven by either type 1 IFN (IFN-1) or IL-1, have been detected in type 1 diabetes, but the dominant innate pathway is still unclear. This study aimed to determine the key innate pathway in type 1 diabetes and assess the whole blood immune stimulation assay as a tool to investigate this. Methods The TruCulture whole blood ex vivo stimulation assay, paired with gene expression and cytokine measurements, was used to characterise changes in the stimulated innate immune response in type 1 diabetes. We applied specific cytokine-induced signatures to our data, pre-defined from the same assays measured in a separate cohort of healthy individuals. In addition, NOD mice were stimulated with CpG and monocyte gene expression was measured. Results Monocytes from NOD mice showed lower baseline vs diabetes-resistant B6.g7 mice, but higher induced IFN-1-associated gene expression. In human participants, ex vivo whole blood stimulation revealed higher induced IFN-1 responses in type 1 diabetes, as compared with healthy control participants. In contrast, neither the IL-1-induced gene signature nor response to the adaptive immune stimulant Staphylococcal enterotoxin B were significantly altered in type 1 diabetes samples vs healthy control participants. Targeted gene-expression analysis showed that this enhanced IFN response was specific to IFN-1, as IFN-γ-driven responses were not significantly different. Conclusions/interpretation Our study identifies increased responsiveness to IFN-1 as a feature of both the NOD mouse model of autoimmune diabetes and human established type 1 diabetes. A stimulated IFN-1 gene signature may be a potential biomarker for type 1 diabetes and used to evaluate the effects of therapies targeting this pathway. Data availability Mouse gene expression data are found in the gene expression omnibus (GEO) repository, accession GSE146452 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146452). Nanostring count data from the human experiments were deposited in the GEO repository, accession GSE146338 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146338). Data files and R code for all analyses are available at https://github.com/rodriguesk/T1D_truculture_diabetologia. Graphical abstractKeywords
Funding Information
- Agence National de Recherche (ANR CE17001002)
- NIH NIDDK (Intramural funding program)
This publication has 58 references indexed in Scilit:
- Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trialsThe Lancet, 2013
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- ROAST: rotation gene set tests for complex microarray experimentsBioinformatics, 2010
- Type I interferons: crucial participants in disease amplification in autoimmunityNature Reviews Rheumatology, 2010
- Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 CellsThe Journal of Immunology, 2009
- Interferon-α initiates type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences, 2008
- Interleukin-1–Receptor Antagonist in Type 2 Diabetes MellitusNew England Journal of Medicine, 2007
- Adjusting batch effects in microarray expression data using empirical Bayes methodsBiostatistics, 2006
- Cytokine-regulated production of the major histocompatibility complex class-III-encoded complement proteins factor B and C4 by human glomerular mesangial cellsHuman Immunology, 1995
- IMMUNOREACTIVE α-INTERFERON IN INSULIN-SECRETING β CELLS IN TYPE 1 DIABETES MELLITUSThe Lancet, 1987